[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Carson AP, Howard DL, Carpenter WR, Taylor YJ, Peacock S, Schenck AP, Godley PA: Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer. J Pain Symptom Manage; 2010 May;39(5):872-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
  • CONTEXT: Androgen deprivation therapy (ADT) is widely used to manage the symptoms of advanced prostate cancer and has been shown to slow the progression of the disease.
  • OBJECTIVES: The purpose of this study was to assess use trends for ADT overall and by type (orchiectomy and luteinizing hormone-releasing hormone [LHRH] agonists) and the factors associated with time to receipt for metastatic prostate cancer.
  • METHODS: Data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry and Medicare claims database were obtained for 5,273 men, aged 65 years and older and diagnosed with Stage IV prostate cancer during 1991-1999 from seven SEER regions.
  • An accelerated failure time regression model with log-normal distribution was used to examine factors associated with mean time to receipt of ADT.
  • Differences were noted in the time to receipt of ADT, with African-American men having a longer mean time to receipt of orchiectomy (time ratio [TR]=1.50; 95% confidence interval [CI]=1.03, 2.17) or LHRH agonist (TR=1.42; 95% CI=1.06, 1.89) than white men.
  • CONCLUSION: African-American men with metastatic prostate cancer were significantly less likely to receive ADT and, when treated, had a slightly longer time to receipt than white men, which has implications for patients and physicians involved in the palliative management of metastatic prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Inc.
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3750-7 [11533098.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 7;93(5):388-95 [11238701.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] J Urol. 2002 Jul;168(1):9-12 [12050481.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Stat Med. 2002 Nov 30;21(22):3493-510 [12407686.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):981-9 [12837834.001]
  • [Cites] Urol Oncol. 2003 Jul-Aug;21(4):245-54 [12954493.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 19;95(22):1702-10 [14625261.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):146-55 [15009794.001]
  • [Cites] Med Care. 2004 Mar;42(3):239-50 [15076823.001]
  • [Cites] Bull N Y Acad Med. 1972 Jun;48(5):751-66 [4555718.001]
  • [Cites] Cancer. 1973 Nov;32(5):1126-30 [4585929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658-62 [6461861.001]
  • [Cites] Urology. 1989 May;33(5 Suppl):45-52 [2523611.001]
  • [Cites] Urology. 1989 May;33(5 Suppl):57-62 [2523612.001]
  • [Cites] Br J Urol. 1991 May;67(5):502-8 [1828183.001]
  • [Cites] Br J Urol. 1997 Feb;79(2):235-46 [9052476.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):320-30 [9669815.001]
  • [Cites] Med Care. 1998 Sep;36(9):1337-48 [9749657.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):538-45 [15612083.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1615-24 [15742331.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):238-44 [16014598.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):839-45 [16788157.001]
  • [Cites] J Urol. 2006 Aug;176(2):526-31 [16813882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):395-402 [16904843.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4448-56 [16983113.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1596-605 [17404365.001]
  • [Cites] J Urol. 2001 Jan;165(1):104-7 [11125375.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(1):CD003506 [11869665.001]
  • (PMID = 20471547.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] ENG
  • [Grant] United States / PHS HHS / / U55/CCR921930-02; United States / NCI NIH HHS / CA / 1U01CA114629; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N02 PC015105; United States / NIMHD NIH HHS / MD / P60MD000244; United States / NCI NIH HHS / CA / U01 CA114629; United States / NIMHD NIH HHS / MD / P60 MD000239; United States / NIMHD NIH HHS / MD / P60 MD000244; United States / NCI NIH HHS / CA / 2R25CA057726; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCI NIH HHS / CA / R25 CA057726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Other-IDs] NLM/ NIHMS362675; NLM/ PMC3878612
  •  go-up   go-down


2. Schleinitz MD, DePalo D, Blume J, Stein M: Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med; 2006 Dec;21(12):1253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can differences in breast cancer utilities explain disparities in breast cancer care?
  • BACKGROUND: Black, older, and less affluent women are less likely to receive adjuvant breast cancer therapy than their counterparts.
  • Whereas preference contributes to disparities in other health care scenarios, it is unclear if preference explains differential rates of breast cancer care.
  • OBJECTIVE: To ascertain utilities from women of diverse backgrounds for the different stages of, and treatments for, breast cancer and to determine whether a treatment decision modeled from utilities is associated with socio-demographic characteristics.
  • PARTICIPANTS: A stratified sample (by age and race) of 156 English-speaking women over 25 years old not currently undergoing breast cancer treatment.
  • DESIGN AND MEASUREMENTS: We assessed utilities using standard gamble for 5 breast cancer stages, and time-tradeoff for 3 therapeutic modalities.
  • We incorporated each subject's utilities into a Markov model to determine whether her quality-adjusted life expectancy would be maximized with chemotherapy for a hypothetical, current diagnosis of stage II breast cancer.
  • RESULTS: Median utilities for the 8 health states were: stage I disease, 0.91 (interquartile range 0.50 to 1.00); stage II, 0.75 (0.26 to 0.99); stage III, 0.51 (0.25 to 0.94); stage IV (estrogen receptor positive), 0.36 (0 to 0.75); stage IV (estrogen receptor negative), 0.40 (0 to 0.79); chemotherapy 0.50 (0 to 0.92); hormonal therapy 0.58 (0 to 1); and radiation therapy 0.83 (0.10 to 1).
  • Utilities for early stage disease and treatment modalities, but not metastatic disease, varied with socio-demographic characteristics.
  • One hundred and twenty-two of 156 subjects had utilities that maximized quality-adjusted life expectancy given stage II breast cancer with chemotherapy.
  • Age over 50, black race, and low household income were associated with at least 5-fold lower odds of maximizing quality-adjusted life expectancy with chemotherapy, whereas women who were married or had a significant other were 4-fold more likely to maximize quality-adjusted life expectancy with chemotherapy.
  • CONCLUSIONS: Differences in utility for breast cancer health states may partially explain the lower rate of adjuvant therapy for black, older, and less affluent women.
  • Further work must clarify whether these differences result from health preference alone or reflect women's perceptions of sources of disparity, such as access to care, poor communication with providers, limitations in health knowledge or in obtaining social and workplace support during therapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] WMJ. 1999 Dec;98(8):37-9 [10639893.001]
  • [Cites] J Gen Intern Med. 2005 Jan;20(1):38-44 [15693926.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1455-61 [11230491.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1577-85 [11401308.001]
  • [Cites] Natl Vital Stat Rep. 2001 Sep 21;49(8):1-113 [11591077.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):471-3 [11929941.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1759-66 [12365025.001]
  • [Cites] South Med J. 2002 Oct;95(10):1145-8 [12425498.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):134-47 [12491515.001]
  • [Cites] Cancer Metastasis Rev. 2003 Mar;22(1):55-65 [12716037.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(1):21-31 [14531494.001]
  • [Cites] BMC Med Inform Decis Mak. 2001;1:2 [11545684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):34-42 [14697418.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):184-94 [15009798.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):301-7 [15951457.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Decis Making. 2000 Jan-Mar;20(1):72-8 [10638539.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Ann Intern Med. 2003 Jan 21;138(2):90-7 [12529090.001]
  • [Cites] J Eval Clin Pract. 2003 Feb;9(1):69-82 [12558704.001]
  • [Cites] Med Decis Making. 2003 Mar-Apr;23(2):167-76 [12693879.001]
  • [Cites] Prev Med. 2004 Jul;39(1):1-10 [15207980.001]
  • [Cites] CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55 [15224974.001]
  • [Cites] Clin Prostate Cancer. 2004 Jun;3(1):31-7 [15279688.001]
  • [Cites] Health Serv Res. 1972 Summer;7(2):118-33 [5044699.001]
  • [Cites] Med Decis Making. 1982 Winter;2(4):449-62 [7182703.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] Med Care. 1989 Mar;27(3 Suppl):S190-204 [2522159.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):326-31 [8321261.001]
  • [Cites] Med Decis Making. 1993 Jul-Sep;13(3):212-7 [8412549.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1395-402 [8839544.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(3):261-73 [8877006.001]
  • [Cites] Breast Cancer Res Treat. 1996;40(1):65-74 [8888153.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):327-37 [8909641.001]
  • [Cites] Med Decis Making. 1997 Jan-Mar;17(1):21-32 [8994148.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):136-41 [9107608.001]
  • [Cites] Oncol Nurs Forum. 1998 Apr;25(3):555-62 [9568610.001]
  • [Cites] Oncol Nurs Forum. 1998 Jun;25(5):887-95 [9644705.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1409-15 [10451447.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1047-53 [10526998.001]
  • [Cites] Med Care. 2005 Feb;43(2):141-8 [15655427.001]
  • [Cites] Med Care. 2000 Sep;38(9 Suppl):II160-4 [10982102.001]
  • (PMID = 16961753.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NICHD NIH HHS / HD / HD43447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC1924747
  •  go-up   go-down


3. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL: Outcomes of localized prostate cancer following conservative management. JAMA; 2009 Sep 16;302(11):1202-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of localized prostate cancer following conservative management.
  • CONTEXT: Most newly diagnosed prostate cancers are clinically localized, and major treatment options include surgery, radiation, or conservative management.
  • Although conservative management can be a reasonable choice, there is little contemporary prostate-specific antigen (PSA)-era data on outcomes with this approach.
  • OBJECTIVE: To evaluate the outcomes of clinically localized prostate cancer managed without initial attempted curative therapy in the PSA era.
  • DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study of men aged 65 years or older when they were diagnosed (1992-2002) with stage T1 or T2 prostate cancer and whose cases were managed without surgery or radiation for 6 months after diagnosis.
  • MAIN OUTCOME MEASURES: Ten-year overall survival, cancer-specific survival, and major cancer related interventions.
  • RESULTS: Among men who were a median age of 78 years at cancer diagnosis, 10-year prostate cancer-specific mortality was 8.3% (95% confidence interval [CI], 4.2%-12.8%) for men with well-differentiated tumors; 9.1% (95% CI, 8.3%-10.1%) for those with moderately differentiated tumors, and 25.6% (95% CI, 23.7%-28.3%) for those with poorly differentiated tumors.
  • The use of chemotherapy (1.6%) or major interventions for spinal cord compression (0.9%) was uncommon.
  • CONCLUSIONS: Results following conservative management of clinically localized prostate cancer diagnosed from 1992 through 2002 are better than outcomes among patients diagnosed in the 1970s and 1980s.
  • This may be due, in part, to additional lead time, overdiagnosis related to PSA testing, grade migration, or advances in medical care.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Contemp Clin Trials. 2009 Jan;30(1):81-7 [18783735.001]
  • [Cites] JAMA. 1997 Feb 12;277(6):467-71 [9020270.001]
  • [Cites] J Urol. 2000 Feb;163(2):519-23 [10647669.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1822-3 [11734600.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-49-54 [12187168.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 18;95(12):868-78 [12813170.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):981-9 [12837834.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] J Urol. 2004 Apr;171(4):1520-4 [15017211.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2713-9 [15187052.001]
  • [Cites] Br J Urol. 1992 Feb;69(2):183-7 [1537031.001]
  • [Cites] JAMA. 1992 Apr 22-29;267(16):2191-6 [1556796.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):310-22 [8319164.001]
  • [Cites] N Engl J Med. 1994 Jan 27;330(4):242-8 [8272085.001]
  • [Cites] Biometrics. 1994 Mar;50(1):61-76 [8086616.001]
  • [Cites] Am J Clin Oncol. 2008 Aug;31(4):375-8 [18845997.001]
  • [Cites] Lancet. 1997 Mar 29;349(9056):906-10 [9093251.001]
  • [Cites] N Engl J Med. 2005 Jan 13;352(2):154-64 [15647578.001]
  • [Cites] BJU Int. 2005 May;95(7):956-60 [15839912.001]
  • [Cites] JAMA. 2005 May 4;293(17):2095-101 [15870412.001]
  • [Cites] N Engl J Med. 2005 May 12;352(19):1977-84 [15888698.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53 [16145045.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):355-7 [16507832.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1708-14 [16544313.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Stat Med. 2007 May 20;26(11):2389-430 [17031868.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 2):S14-9 [17644125.001]
  • [Cites] J Urol. 2007 Dec;178(6):2359-64; discussion 2364-5 [17936806.001]
  • [Cites] Semin Radiat Oncol. 2008 Jan;18(1):2-6 [18082582.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):69-74 [18000803.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2696-705 [18160689.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):435-48 [18252677.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1650-9 [18306379.001]
  • [CommentIn] JAMA. 2010 Jan 6;303(1):33-4; author reply 34 [20051566.001]
  • (PMID = 19755699.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116399-03; United States / NCI NIH HHS / CA / CA116399-04; United States / NCI NIH HHS / CA / P30 CA072720; United States / NCI NIH HHS / CA / CA116399-03; United States / NCI NIH HHS / CA / R01 CA116399; United States / NCI NIH HHS / CA / CA-72720-10; United States / NCI NIH HHS / CA / R01 CA116399-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS172636; NLM/ PMC2822438
  •  go-up   go-down


Advertisement
4. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA; 2008 Jul 9;300(2):173-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival following primary androgen deprivation therapy among men with localized prostate cancer.
  • CONTEXT: Despite a lack of data, increasing numbers of patients are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management for the treatment of localized prostate cancer.
  • OBJECTIVE: To evaluate the association between PADT and survival in elderly men with localized prostate cancer.
  • DESIGN, SETTING, AND PATIENTS: A population-based cohort study of 19,271 men aged 66 years or older receiving Medicare who did not receive definitive local therapy for clinical stage T1-T2 prostate cancer.
  • These patients were diagnosed in 1992-2002 within predefined US geographical areas, with follow-up through December 31, 2006, for all-cause mortality and through December 31, 2004, for prostate cancer-specific mortality.
  • MAIN OUTCOME MEASURES: Prostate cancer-specific survival and overall survival.
  • RESULTS: Among patients with localized prostate cancer (median age, 77 years), 7867 (41%) received PADT, and 11,404 were treated with conservative management, not including PADT.
  • During the follow-up period, there were 1560 prostate cancer deaths and 11,045 deaths from all causes.
  • Primary androgen deprivation therapy was associated with lower 10-year prostate cancer-specific survival (80.1% vs 82.6%; hazard ratio [HR], 1.17; 95% confidence interval [CI], 1.03-1.33) and no increase in 10-year overall survival (30.2% vs 30.3%; HR, 1.00; 95% CI, 0.96-1.05) compared with conservative management.
  • However, in a prespecified subset analysis, PADT use in men with poorly differentiated cancer was associated with improved prostate cancer-specific survival (59.8% vs 54.3%; HR, 0.84; 95% CI, 0.70-1.00; P = .049) but not overall survival (17.3% vs 15.3%; HR, 0.92; 95% CI, 0.84-1.01).
  • CONCLUSION: Primary androgen deprivation therapy is not associated with improved survival among the majority of elderly men with localized prostate cancer when compared with conservative management.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):981-9 [12837834.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [Cites] Urology. 2002 Jul;60(1):115-9 [12100935.001]
  • [Cites] J Urol. 2004 Sep;172(3):923-7 [15310999.001]
  • [Cites] JAMA. 2004 Aug 18;292(7):821-7 [15315996.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67 [15367568.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4109-18 [15483020.001]
  • [Cites] Surg Gynecol Obstet. 1967 May;124(5):1011-7 [6022476.001]
  • [Cites] Cancer Res. 1981 Dec;41(12 Pt 1):5070-5 [7307008.001]
  • [Cites] Vital Health Stat 2. 1991 Nov;(112):1-102 [1808847.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Methods Inf Med. 1993 Nov;32(5):382-7 [8295545.001]
  • [Cites] JAMA. 1995 Aug 23-30;274(8):626-31 [7637143.001]
  • [Cites] J Urol. 1996 Nov;156(5):1714-8 [8863577.001]
  • [Cites] Br J Urol. 1997 Feb;79(2):235-46 [9052476.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):295-300 [9233866.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 1):1871-6 [15540741.001]
  • [Cites] N Engl J Med. 2005 Jan 13;352(2):154-64 [15647578.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1151-6 [15657128.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1615-24 [15742331.001]
  • [Cites] J Urol. 2005 Sep;174(3):827-34 [16093964.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Sep;63(3):239-50 [16117808.001]
  • [Cites] BJU Int. 2006 Feb;97(2):247-54 [16430622.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1708-14 [16544313.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1868-76 [16622261.001]
  • [Cites] Cancer Sci. 2006 Apr;97(4):243-7 [16630114.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):839-45 [16788157.001]
  • [Cites] BJU Int. 2006 Sep;98(3):573-9 [16925756.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4190-5 [16943536.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4448-56 [16983113.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):278-85 [17227979.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2420-5 [17557956.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9089-96 [17909013.001]
  • [Cites] N Engl J Med. 1999 Dec 9;341(24):1781-8 [10588962.001]
  • [Cites] J Urol. 2000 Feb;163(2):519-23 [10647669.001]
  • [Cites] Ann Intern Med. 2000 Apr 4;132(7):566-77 [10744594.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1064-70 [11181670.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1822-3 [11734600.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):599-603 [11836291.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):430-7 [11904315.001]
  • [CommentIn] JAMA. 2009 Jan 7;301(1):35; author reply 35 [19126809.001]
  • [CommentIn] Nat Clin Pract Urol. 2008 Dec;5(12):648-9 [18936786.001]
  • [CommentIn] JAMA. 2009 Jan 7;301(1):35-6 [19126808.001]
  • [ErratumIn] JAMA. 2009 Jan 7;301(1):38
  • (PMID = 18612114.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116399-03; United States / NCI NIH HHS / CA / P30 CA072720; United States / NCI NIH HHS / CA / R01 CA116399-01A1; United States / NCI NIH HHS / CA / R01 CA116399-02; United States / NCI NIH HHS / CA / CA116399-03; United States / NCI NIH HHS / CA / R01 CA116399; United States / NCI NIH HHS / CA / CA116399-02; United States / NCI NIH HHS / CA / CA-72720-10; United States / NCI NIH HHS / CA / CA116399-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  • [Other-IDs] NLM/ NIHMS92658; NLM/ PMC2645653
  •  go-up   go-down


5. Curtis KK, Adam TJ, Chen SC, Pruthi RK, Gornet MK: Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review. Aging Male; 2008 Dec;11(4):157-61
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
  • OBJECTIVE: Haemoglobin levels often decline into the anaemic range with androgen deprivation therapy (ADT).
  • We conducted a chart review of patients receiving ADT for metastatic prostate cancer to assess anaemia-related symptoms.
  • METHODS: 135 stage IV prostate cancer cases were reviewed for treatment type; haemoglobin values before and after treatment; and symptoms of anaemia.
  • Mean haemoglobin levels before and after for all treatment forms, for leuprolide alone, and for combination leuprolide/bicalutamide were calculated and evaluated for significant differences.
  • The numbers of patients developing symptoms were recorded and the effects of specific therapies evaluated.
  • Leuprolide and bicalutamide combination treatment caused a mean decline of -0.78 g/dL (p=0.0426).
  • Contingency analysis with Fisher's exact test shows patients receiving leuprolide therapy alone versus other forms of ADT were significantly less likely to have symptoms (chi(2)=0.0190).
  • [MeSH-major] Androgen Antagonists / adverse effects. Anemia / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Anilides / adverse effects. Anilides / therapeutic use. Combined Modality Therapy. Goserelin / adverse effects. Goserelin / therapeutic use. Hemoglobins / analysis. Humans. Leuprolide / adverse effects. Leuprolide / therapeutic use. Linear Models. Male. Neoplasm Metastasis. Nitriles / adverse effects. Nitriles / therapeutic use. Retrospective Studies. Tosyl Compounds / adverse effects. Tosyl Compounds / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937151.001).
  • [ISSN] 1473-0790
  • [Journal-full-title] The aging male : the official journal of the International Society for the Study of the Aging Male
  • [ISO-abbreviation] Aging Male
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Hemoglobins; 0 / Nitriles; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; A0Z3NAU9DP / bicalutamide; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


6. Fusi A, Procopio G, Della Torre S, Ricotta R, Bianchini G, Salvioni R, Ferrari L, Martinetti A, Savelli G, Villa S, Bajetta E: Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori; 2004 Nov-Dec;90(6):535-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options in hormone-refractory metastatic prostate carcinoma.
  • Prostate cancer represents one of the most important health problems in industrialized countries.
  • It is the second leading cause of cancer-related death in the United States.
  • Therapeutic options are different according to the stage of the disease at the diagnosis.
  • Patients with localized disease may be treated with surgery or radiation, whereas the treatment for patients with a metastatic disease is purely palliative.
  • Hormonal treatment represents the standard therapy for stage IV prostate cancer, but patients ultimately become unresponsive to androgen ablation and are classified as hormone-refractory prostate cancer patients.
  • The important thing is that we understand these mechanisms to define potential therapeutic agents for the treatment of hormone-refractory prostate cancer patients.
  • Conventional options for patients with hormone-refractory prostate cancer include secondary hormone therapy, radiotherapy and cytotoxic chemotherapy.
  • Therefore, there is no standard therapy for these patients, thus we need new approaches which should be studied in clinical trials.
  • The evaluation and incorporation of new agents into current treatment regimens could have a role in the treatment of hormone-refractory prostate cancer, but their efficacy has not yet been demonstrated.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Receptors, Androgen / drug effects. Receptors, Androgen / metabolism
  • [MeSH-minor] Clinical Trials, Phase II as Topic. Drug Resistance, Neoplasm. Estramustine / therapeutic use. Gene Expression Regulation, Neoplastic. Humans. Male. Mitoxantrone / therapeutic use. Neoplasm Staging. Palliative Care. Survival Analysis. Taxoids / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762353.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Androgen; 0 / Taxoids; 35LT29625A / Estramustine; BZ114NVM5P / Mitoxantrone
  • [Number-of-references] 120
  •  go-up   go-down


7. Buskirk SJ, Pisansky TM, Atkinson EJ, Schild SE, O'Brien PC, Wolfe JT, Zincke H: Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy. Mayo Clin Proc; 2001 Jul;76(7):702-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
  • OBJECTIVE: To evaluate the outcome of patients with pathologic stage IV prostate cancer treated with androgen ablation plus external-beam radiation therapy.
  • PATIENTS AND METHODS: Sixty consecutive patients treated between August 1986 and February 1995 with androgen ablation plus radiation therapy for stage IV (T1-4 N1 M0) adenocarcinoma of the prostate were selected for outcome analysis in this retrospective study.
  • The 4 remaining patients had pelvic adenopathy on computed tomography, which was confirmed histologically in all patients.
  • The median pretreatment prostate-specific antigen (PSA) level was 28.8 ng/mL (mean, 55 ng/ mL; range, 0.1-428 ng/mL).
  • All patients received radiation therapy to the prostate, and 29 (48%) had pelvic node radiation.
  • Biochemical failure was defined according to the American Society for Therapeutic Radiology and Oncology criteria of 3 successive increases in the PSA level.
  • Thirteen patients (22%) died of causes related to prostate cancer.
  • CONCLUSIONS: This observational case series of patients treated with the combination of external-beam radiation therapy and permanent androgen ablation for pathologic stage IV prostate cancer suggests that the addition of androgen deprivation therapy to radiation therapy may improve disease outcome.
  • In the absence of randomized trial results, these observations may be beneficial in clinical decision making.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Androgen Antagonists / therapeutic use. Lymphatic Metastasis. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Humans. Life Tables. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Prostate-Specific Antigen / blood. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11444402.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


8. Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump DL: Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer; 2010 May 1;116(9):2132-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.
  • On the basis of these data, the authors conducted a phase 2 trial of intravenous (iv) calcitriol at a dose of 74 microg weekly (based on a recent phase 1 trial) and dexamethasone in patients with castration-resistant prostate cancer (CRPC).
  • METHODS: A 2-stage Kepner-Chang design was used.
  • Oral dexamethasone at a dose of 4 mg was given weekly on Days 1 and 2, and iv calcitriol (74 microg over 1 hour) was administered weekly on Day 2 from 4 to 8 hours after the dexamethasone dose in patients with CRPC.
  • Laboratory data were monitored weekly, and renal sonograms, computed tomography scans, and bone scans were obtained every 3 months.
  • Disease response was assessed by using the Response Evaluation Criteria in Solid Tumors (RECIST) and standard criteria for prostate-specific antigen (PSA) response.
  • Fourteen patients had progressive disease, 2 patients refused to continue treatment (after 64 days and 266 days), and 2 patients remain on the trial (for 306 days and 412 days).The median time to disease progression was 106 days (95% confidence interval, 80-182 days).
  • No treatment-related deaths were noted.
  • CONCLUSIONS: High-dose, iv calcitriol at a dose of 74 microg weekly in combination with dexamethasone was well tolerated but failed to produce a clinical or PSA response in men with CRPC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcitriol / administration & dosage. Dexamethasone / administration & dosage. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Calcium / blood. Creatinine / blood. Drug Administration Schedule. Humans. Injections, Intravenous. Male. Middle Aged. Prostate-Specific Antigen / blood. Retreatment

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20166215.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; AYI8EX34EU / Creatinine; EC 3.4.21.77 / Prostate-Specific Antigen; FXC9231JVH / Calcitriol; SY7Q814VUP / Calcium
  •  go-up   go-down


9. Kumi-Diaka J: Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and beta-lapachone. Biol Cell; 2002 Feb;94(1):37-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and beta-lapachone.
  • A wide spectrum of anti-cancer activity of genistein and beta-lapachone in various tumors has been reported in single treatments.
  • In this study the combined effects of genistein and beta-lapachone on the chemosensitivity of LNCaP and PC3 human prostate cancer cells was determined in vitro, using 3-[4,5-dimethylthiazol-2-yl]-2-,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) to study treatment-induced growth inhibition and cytotoxicity and, annexin V-fluoresceine (FI) and terminal deoxyribonucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-propidium iodide (PI) assays to determine potential treatment-induced apoptosis and/or necrosis.
  • The results showed: i) that both PC3 and LNCaP are sensitive to single and combination treatments regardless of hormone sensitivity status, ii) that treatment induced dual death pathways (apoptosis and necrosis) in both cell types, iii) that growth inhibition in both cell types correlated positively with cell death via apoptosis at lower drug concentrations and necrosis at higher concentrations, iv) that combination of genistein and beta-lapachone had synergistic inhibitory effects on growth and proliferation in both cell types.
  • The synergistic inhibitory effect was correlated positively with treatment-induced cell death via apoptosis and necrosis.
  • The overall results indicate that combination treatments with beta-lapachone and genistein are more potent in killing both PC3 and LNCaP cancer cells than treatment with either genistein or beta-lapachone alone. beta-lapachone acts at the G1 and S phase checkpoints in the cell cycle, while genistein induces cell cycle arrest at the G2-M stage.
  • The current results are therefore in agreement with the hypothesis that drug combinations that target cell cycles at different critical checkpoints would be more effective in causing cell death.
  • This result provides a rationale for in vivo studies to determine whether beta-lapachone-genistein combination will provide effective chemotherapy for prostate cancer, regardless of the tumor sensitivity to hormone.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12000145.001).
  • [ISSN] 0248-4900
  • [Journal-full-title] Biology of the cell
  • [ISO-abbreviation] Biol. Cell
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Estrogens, Non-Steroidal; 0 / Isoflavones; 0 / Naphthoquinones; 1POG3SCN5T / genistin; 4707-32-8 / beta-lapachone
  •  go-up   go-down


10. Bunn PA Jr, Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, Piazza G, Whitehead CM, Pamukcu R, Thompson W, Alila H: Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol; 2002 Feb;29(1 Suppl 4):87-94
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
  • Lung cancer is the leading cause of cancer death in the United States.
  • About one third of patients have stage IV disease with metastases to distant organs at the time of diagnosis.
  • Current chemotherapy combinations improve the survival and quality of life for patients with advanced non-small cell lung cancer.
  • With two-drug combinations, median survival is increased to 8 months or more and 1-year survival is increased to 35% to 40%.
  • The improvements created by current therapies led to studies of chemotherapy in the second-line setting.
  • Docetaxel has been shown to improve survival of patients who failed platinum-based chemotherapy and was approved by the U.S.
  • Food and Drug Administration for therapy in this setting.
  • Therefore, new therapies are urgently needed.
  • Exisulind is a novel oral anticancer agent that holds promise for the treatment of patients with advanced non-small cell lung cancer.
  • Exisulind was originally developed as a chemoprevention agent for colorectal cancer.
  • Subsequent preclinical studies showed that exisulind also inhibited the growth of human breast, prostate, and lung cancers.
  • These observations lead to the studies of the combination of exisulind and docetaxel in preclinical and clinical studies in human lung cancer described in this article.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Sulindac / analogs & derivatives. Taxoids
  • [MeSH-minor] Administration, Oral. Animals. Cell Cycle. Disease Models, Animal. Humans. Immunohistochemistry. Mice. Rats. Survival Analysis. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11894018.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46934; United States / NCI NIH HHS / CA / CA58187
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 184SNS8VUH / Sulindac; K619IIG2R9 / sulindac sulfone; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 25
  •  go-up   go-down


11. Patel K, Brahmbhatt V, Ramu V: Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases. Tenn Med; 2005 Feb;98(2):83-5, 89
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
  • A 74-year old white man was undergoing treatment with palliative chemotherapy for Stage IV Prostate Adenocarcinoma with multiple osteoblastic metastases.
  • Before starting Zoledronic acid therapy, the patient's serum calcium level was 6.9 mg/dl.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Bone Resorption / prevention & control. Diphosphonates / adverse effects. Hypocalcemia / chemically induced. Imidazoles / adverse effects
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Humans. Male. Pain / drug therapy. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779196.001).
  • [ISSN] 1088-6222
  • [Journal-full-title] Tennessee medicine : journal of the Tennessee Medical Association
  • [ISO-abbreviation] Tenn Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


12. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA; 2003 Oct 22;290(16):2149-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
  • CONTEXT: More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined.
  • In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiographic tumor shrinkages with gefitinib.
  • Patients (N = 221) had either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens.
  • MAIN OUTCOME MEASURES: Improvement of NSCLC symptoms (2-point or greater increase in score on the summed lung cancer subscale of the Functional Assessment of Cancer Therapy-Lung [FACT-L] instrument) and tumor regression (>50% decrease in lesion size on imaging studies).
  • CONCLUSIONS: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.


13. Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, Wang Y, Prostate Cancer Clinical Trials Consortium: Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC).
  • METHODS: Chemotherapy-naïve metastatic CRPC patients received sagopilone 16 mg/m<sup>2</sup> IV over 3 hours every 21 days and prednisone 5 mg PO BID.
  • The Simon 2-Stage design required 3 responders among the first 13 evaluable patients and 13 responders among the first 46 evaluable patients to declare the agent of interest for further investigation.
  • CONCLUSIONS: Sagopilone is active in metastatic chemotherapy-naïve CRPC patients, with probability of PSA decline, measurable disease responses, and PFS approximating the current standard of docetaxel + prednisone.
  • Further evaluation of this agent in prostate cancer is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962969.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Wojtowicz M, Rothermel JD, Anderson J, Todd M, Rubin EH, Dipaola RS: Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus estramustine in patients with advanced cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):4623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus estramustine in patients with advanced cancer.
  • : 4623 Background: Estramustine in combination with taxanes has demonstrated synergistic antitumor activity in patients (pts) with hormone-refractory prostate cancer.
  • However, taxanes are associated with hematologic toxicity and the development of drug resistance.
  • METHODS: We investigated the MTD of EPO906 plus estramustine in pts with advanced cancer.
  • Pts with stage III/IV solid tumors and a performance status ≤ 2 were eligible.
  • Pts received weekly oral estramustine 280 mg BID days 1 - 3 and EPO906 starting at 0.5 mg/m<sup>2</sup> via 5-min IV infusion weekly on day 2 for 3 wk followed by 1 wk of rest.
  • Tumor types are predominantly prostate and breast cancer.
  • All pts except 1 had received prior taxane therapy.
  • Preliminary tumor assessment showed 1 pt with PR and 8 pts with SD (3 for 4 months; 5 for 2 months).
  • CONCLUSION: Preliminary results suggest that EPO906 plus estramustine is generally well tolerated in pts with advanced cancer.
  • Future studies will fully characterize the role of EPO906 in combination with estramustine in the treatment of advanced cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015742.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Vidal M, Ferrer A, Serrano S, Tobeña M, Pajares I, Lopez D, Millastre E, Ruiz-Echarri M, Lambea J, Tres A: Fever in cancer patients as a cause of attendance in emergency room. J Clin Oncol; 2009 May 20;27(15_suppl):e20706

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fever in cancer patients as a cause of attendance in emergency room.
  • : e20706 Background: Normal human body temperature displays a circadian rhythm, ranging from 36.1 C or lower in predawn hours to 37.4 C or higher in the afternoon.
  • Cancer patients frequently experience fever.
  • Nearly two-thirds of the cases of fever in patients with prolonged neutropenia could be attributed to infection, a major cause of morbidity in cancer patients.
  • PURPOSE: The aim of our study is to evaluate the prevalence of cancer patients who were attended in the emergency room for fever, the diagnosis and clinical management.
  • METHODS: From October 2007 to October 2008, 560 cancer patients were seen in the emergency department of the University Hospital of Zaragoza.
  • 63% of patients were stage IV.
  • Cancer tumor type, 35 had lung cancer (35.7%), 14 had breast cancer (14.3%), 9 had colorectal cancer (9.2%), 9 had urothelial cancer (9.2%), 5 had head neck cancer (5.1%), 5 had pancreatic cancer (5.1%), 3 had esophageal cancer (3%), 2 had prostate cancer (2%), and 14,3% had other neoplasm.
  • 18 patients (18.36%) had been received chemotherapy treatment in a period of 10 days before. they were attended in emergency room.
  • Considering all the patients who presented with fever: 45 patients were sent home with new treatment (45,9%), 6 patients were observed for 24 hours in the emergency room (6.2%) and 47 patients required admission to the hospital (47.9%).
  • CONCLUSIONS: Fever in cancer patients remains a challenge, and the differentiation between infectious and non-infectious causes at onset of fever is very difficult.
  • Infection in the immunocompromised host is a serious clinical situation due to high morbimortality and is one of the most frequent complications in the patient with cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Pinski JK, Goldman B, Dorff T, Mack P, Lara P Jr, van Veldhuizen P, Quinn D, Hussain MH, Thompson IM: SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration- resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration- resistant prostate cancer (CRPC).
  • : 5143 Background: IL-6 facilitates cancer cell survival via pleiotrophic effects on proliferation, apoptosis, angiogenesis, differentiation, and chemo-resistance.
  • METHODS: Eligible pts had one prior chemotherapy, Zubrod performance status 0-2, and adequate end-organ function.
  • Regimen: CNTO328 6 mg/kg IV q2 weeks x 12 cycles.
  • Accrual was completed in 2 stages, with planned accrual of 20 eligible pts in the first stage and 40 overall.
  • RESULTS: Of 62 pts, 54 were eligible; all had received prior taxane therapy.
  • Declining CRP levels during treatment reflect biologic activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ohike N, Nakashima M, Shiokawa A, Morohoshi T, Maass N, Miki Y, Nagasaki K: Prognostic significance of tumor suppressor gene maspin in pulmonary adenocarcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):7162

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7162 Background Maspin is a unique member of the serine protease inhibitor family with tumor suppressive potential in breast and prostate cancer.
  • Recent studies have shown that loss of maspin expression correlates with progression and metastasis of tumors and poor prognoses for patients with several types of cancers.
  • In the surrounding pulmonary tissues, alveolar epithelial cells lacked maspin expression, but maspin staining was usually present in bronchial basal cells and occasionally present in surface bronchial epithelial cells.
  • Maspin expression was not associated significantly with most clinicopathological variables including sex, age, tumor size, primary tumor, lymph node metastasis, visceral pleural invasion, pulmonary metastasis, stage grouping and p53 expression.
  • The difference in the 5-year survival rate was more significant in stage II-IV patients (maspin-positive group, 53%; -negative group, 16%, p = 0.049).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014213.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Beardsley EK, Saad F, Eigl B, Venner P, Hotte S, Winquist E, Ko YJ, Sridhar SS, Chi KN: A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol; 2009 May 20;27(15_suppl):5139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel.
  • : 5139 Background: Chemotherapy for pts with CRPC who have progressed after docetaxel remains to be defined.
  • METHODS: Multicenter, 2-stage design.
  • Patupilone was initially given 10mg/m <sup>2</sup> IV every 3 weeks.
  • Baseline characteristics (range): median age 67 (47-85), PSA 212 (2.6-11520), hemoglobin 118 (89-160), median time to progression after docetaxel 1.0 months (0.0-6.0), number of prior chemotherapy regimens 1:2:3+ in 45:28:10 pts, ECOG PS 0-1:2 in 73:10 pts, disease in bone/lymph nodes/viscera in 76/47/14 pts respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964422.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Chi KN, Hotte SJ, Yu E, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Eisenhauer E, National Cancer Institute of Canada Clinical Trials Group: Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer.
  • OGX is a 2'-methoxyethyl antisense that potentiates chemotherapy in xenografts and inhibits clusterin expression at doses of <640 mg.
  • METHODS: Pts with CRPC and chemo-naive received docetaxel (DOC) 75mg/m<sup>2</sup> q3w + OGX 640mg IV weekly + prednisone (Arm A) or DOC + prednisone (Arm B) in a single stage randomized phase II design.
  • At this analysis time, all pts are off therapy and 49 have died.
  • Variables predictive of OS on multivariate analysis: PS 0 vs 1 (p = 0.0002), presence of visceral metastasis (p = 0.006) and treatment assignment (HR = 0.54 [0.29-0.97], p = 0.04).
  • Supported by a grant from the NCI-Canada/Canadian Cancer Society.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962904.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Morgenfeld EL, Rivarola E, Cataldi C, Gil Deza E, Tognelli F, Polo S, De Romedi M, Santillan D, Ares S, Gercovich FG: Comparison between patient's (pt) and doctor's (dr) expectation about the efficacy of cancer treatment (tx). A prospective blind mis-match analysis. J Clin Oncol; 2004 Jul 15;22(14_suppl):8248

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between patient's (pt) and doctor's (dr) expectation about the efficacy of cancer treatment (tx). A prospective blind mis-match analysis.
  • : 8248 Background: Few data about cancer pt's and clinical oncologist's expectations about the efficacy of a systemic treatment are available.
  • METHODS: A written self-report questionnaire was distributed within pts attending to our cancer clinic during a two-week period.
  • Pts were asked about their expectations from cancer treatment i.e. cure, prolongation of life or improving quality of life.
  • The doctors were blindly requested to provide their reason for the prescription of a given chemotherapy regimen..
  • Cancer diagnosis included: breast 114 (41.8%), colo-rectal 45 (16.5%), prostate 35 (12.8%), lung 11 (4%), ovary 9 (3.3%), lymphoma 8 (2.9%) head and neck 6 (2.2%), testes 6 (2.2%) and miscellaneous 39 (14.2%).
  • One hundred and seventy four pts (63.7%) had stage III-IV disease while 99 (36.3%) had stage I-II disease.
  • One hundred and seventy six pts (72.7%) stated that they expected that treatment would cure them, while 53 pts (21.9%) felt that tx would help to prolong life.
  • The dr's expectations for treatment outcome were comparable to that of their patients' in 49% of the cases.
  • There was 90% agreement between pts and drs for stage I and II pts (p=0.001) and less than 30% agreement for stage III/IV pts (p=0.001).
  • However, drs were more pesimistic than pts in 44.3% of stage III/IV while they have a more optimistic vision for 7% of stage I-II.
  • CONCLUSIONS: In our setting, cancer patients are highly satisfied with the doctor-patient interaction, however their high expectations for cure may be unrealistic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016645.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ferreira Filho AF, Wunder AP, da Silva DL, Slomka L, Machado MW, Dos Santos MP, Graeff S, Freitas D, Friedrich A: Analysis of resilience scores in a cohort of solid tumors ambulatory cancer patients in chemotherapy treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e20736

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of resilience scores in a cohort of solid tumors ambulatory cancer patients in chemotherapy treatment.
  • Very scanty data exists regarding its quantification and distribution in cancer patients.
  • The objective of this study is to evaluate and describe resilience scores in a population of ambulatory solid tumors cancer patients receiving chemotherapy treatment.
  • During the year 2008, this scale was applied to 48 ambulatory solid tumor cancer patients in chemotherapy treatment at Oncosinos / Hospital Regina in Novo Hamburgo, Brazil.
  • The most common cancer types were: breast (48%), colo-rectal (21%) and prostate (8%).
  • Most patients (47%) had stage IV disease and were in palliative chemotherapy treatment.
  • Stage III cancer was present in 40% and stages I and II in 13% of patients.
  • No statistical differences in the mean resillience scores were detected between groups of patients as defined by: sex (P=0.11), age > or < 50 years (P=0.9), cancer type (P= 0.78), disease staging (P= 0.9), or the chemotherapy treatment intention, if palliative or curative (P=0.91).
  • Our results suggest that the total resillience score is an intrinsic individual characteristic that is independent of cancer stage, cancer type, age and sex of the patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962006.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Tkachev SI, Matveev VB, Trofimova OP, Nazarenko AV, Pylova IV, Priamikova IuI: [Conformal radiotherapy for prostate cancer]. Vopr Onkol; 2010;56(2):215-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conformal radiotherapy for prostate cancer].
  • Data are presented on a retrospective comparison of the results of remote radiotherapy and combined treatment of prostate cancer (T2T4NxM0) (88) at the Center's Clinics (1999-2003).
  • In group 1 (n=37), contemporary radiotherapy was administered--TTD--up to 44 Gy (stage I) and up to 66-70 Gy (stage II).
  • In group 2 (n=51), contemporary radiotherapy was supplemented with inhalation of radioprotector GGS-9--TTD--up to 44 Gy plus GGS-9 (stage I) and up to 72-76 Gy plus conformaton radiotherapy (3D CRT) (stage II).
  • When GGS-9 was used at stage I the rate of acute radiation injury dropped from 56.7% in group 1 to 11.7% in group 2, (p=0.0001).
  • The latter treatment was followed by higher 5-year recurrence-free survival (94.2%) as compared with contemporary radiotherapy (73%), (p=0.0001).
  • Owing to use of 3D CRT, dose distribution was improved as volume and dosage for organs at risk of irradiation decreased, while TTD increased up to 72-76 Gy unaccompanied by a rise in early-onset injuries.
  • [MeSH-major] Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / administration & dosage. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Dose-Response Relationship, Radiation. Drug Administration Schedule. Humans. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Staging. Prostate-Specific Antigen / blood. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Intensity-Modulated. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552901.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


23. Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason MD, Morgan RC, Sanders K, Royston P: Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials; 2009 Jun 11;10:39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.
  • BACKGROUND: The multi-arm multi-stage (MAMS) trial is a new paradigm for conducting randomised controlled trials that allows the simultaneous assessment of a number of research treatments against a single control arm.
  • Prostate cancer is the most common tumour in men and there is a need to improve outcomes for men with hormone-sensitive, advanced disease as quickly as possible.
  • The MAMS design will potentially facilitate evaluation and testing of new therapies in this and other diseases.
  • METHODS: STAMPEDE is an open-label, 5-stage, 6-arm randomised controlled trial using MAMS methodology for men with prostate cancer.
  • CONCLUSION: It is possible to use the MAMS design to initiate and undertake large scale cancer trials.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy. Randomized Controlled Trials as Topic / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Data Interpretation, Statistical. Diphosphonates / therapeutic use. Drug Therapy, Combination. Humans. Imidazoles / therapeutic use. Male. Software. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1126-34 [11308265.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3972-82 [12351594.001]
  • [Cites] Stat Med. 2003 Jul 30;22(14):2239-56 [12854091.001]
  • [Cites] J Urol. 2004 Jul;172(1):141-5 [15201755.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):669-85 [7661937.001]
  • [Cites] N Engl J Med. 1998 Oct 8;339(15):1036-42 [9761805.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):711-22 [15721478.001]
  • [Cites] Lancet. 2009 Jan 24;373(9660):301-8 [19091394.001]
  • [Cites] BJU Int. 2009 Feb;103(4):464-9 [18990168.001]
  • [Cites] Health Technol Assess. 2005 Mar;9(7):1-238, iii-iv [15763038.001]
  • [Cites] BJU Int. 2005 Nov;96(7):985-9 [16225513.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1215-21 [16278665.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):472-9 [16750497.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10):1344-50 [16730974.001]
  • [Cites] Biom J. 2006 Aug;48(4):635-43 [16972715.001]
  • [Cites] JAMA. 2006 Nov 15;296(19):2329-35 [17105795.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):143-52 [17630037.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5218-24 [18024867.001]
  • [Cites] J Clin Epidemiol. 2008 Mar;61(3):203-4 [18226741.001]
  • [Cites] J Clin Epidemiol. 2008 Mar;61(3):241-6 [18226746.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1987-92 [18421050.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 3;100(17):1204-14 [18728279.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Oct;20(8):577-81 [18760574.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1572-8 [19002178.001]
  • (PMID = 19519885.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN78818544; ClinicalTrials.gov/ NCT00268476
  • [Grant] United Kingdom / Cancer Research UK / / 10588; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / / 3804; United Kingdom / Medical Research Council / / MC/ U122861330; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / G0501019; United Kingdom / Medical Research Council / / G0500966
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Taxoids; 15H5577CQD / docetaxel; 6XC1PAD3KF / zoledronic acid
  • [Other-IDs] NLM/ PMC2704188
  •  go-up   go-down


24. Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD, Cancer and Leukemia Group B Study 9153: Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer; 2006 Dec 15;107(12):2817-25
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
  • METHODS: For this multicenter, single-arm, Phase II study, 44 patients with treatment-naive, stage III or IV, indolent NHL (International Working Formulation subtypes A, B, and C) were enrolled.
  • Four late malignancies (prostate adenocarcinoma, ductal carcinoma in situ, and myelodysplasia) and 4 patients with large cell transformation were reported.
  • CONCLUSIONS: 2-CdA is an active, well-tolerated therapy for patients with untreated, indolent NHL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cladribine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 17120198.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA47555; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


25. Green CR, Hart-Johnson T: Cancer pain: an age-based analysis. Pain Med; 2010 Oct;11(10):1525-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer pain: an age-based analysis.
  • OBJECTIVE: Although cancer pain (consistent and breakthrough pain [BTP; pain flares interrupting well-controlled baseline pain]) is common among cancer patients, its characteristics, etiology, and impact on health-related quality of life (HRQOL) across the lifespan are poorly understood.
  • DESIGN: This longitudinal study examines age-based differences and pain-related interference in young and old patients with cancer-related pain over 6 months.
  • Patients in the community with stage III or IV breast, prostate, colorectal, or lung cancer, or stage II-IV multiple myeloma with BTP completed surveys (upon initial assessment, 3 and 6 months) assessing consistent pain, BTP, depressed affect, active coping ability, and HRQOL using previously validated measures.
  • CONCLUSIONS: These data provide evidence for the significant toll of cancer pain on overall health and well-being of young and old adults alike but demonstrate an increased toll for younger adults (especially financially).
  • Beyond race and gender disparities, further health care disparities in the cancer and cancer pain were identified by age, illustrating the need for additional research across the lifespan in diverse cancer survivors.
  • [MeSH-major] Neoplasms / complications. Pain, Intractable / drug therapy. Pain, Intractable / epidemiology. Palliative Care

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Wiley Periodicals, Inc.
  • (PMID = 21199305.001).
  • [ISSN] 1526-4637
  • [Journal-full-title] Pain medicine (Malden, Mass.)
  • [ISO-abbreviation] Pain Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Kurbacher CM, Kurbacher JA, Cramer EM, Rhiem K, Mallman PK, Reichelt R, Reinhold U, Stier U, Cree IA: Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. Oncology (Williston Park); 2005 Apr;19(4 Suppl 2):23-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma.
  • Adjuvant treatment with continuous low-dose GM-CSF has been shown to prolong survival of stage III/IV melanoma patients.
  • Data on continuous low-dose GM-CSF therapy in tumors other than prostate cancer are still lacking.
  • This pilot trial was initiated in order to evaluate the efficacy and tolerability of continuous low-dose GM-CSF as salvage in various chemotherapy-refractory carcinomas.
  • Their malignancies included metastatic breast cancer, recurrent ovarian carcinoma, metastatic endometrial carcinoma, and recurrent squamous cell cancer of the cervix uteri.
  • Therapy was continued until progression or refusal by the patient.
  • Notably, 6 of 7 responders but only 1 of 8 patients with disease progression developed leukocytosis during therapy.
  • Therefore, we conclude that continuous low-dose GM-CSF has substantial activity in heavily pretreated patients with either metastatic breast cancer or female genital tract cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Endometrial Neoplasms / drug therapy. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Ovarian Neoplasms / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Disease Progression. Female. Humans. Neoplasm Recurrence, Local / prevention & control. Pilot Projects. Recombinant Proteins. Salvage Therapy


27. Masue N, Hasegawa Y: [Giant prostate carcinoma treated effectively with endocrine therapy: case report]. Hinyokika Kiyo; 2007 Feb;53(2):133-5
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
  • Computed tomography (CT) and magnetic resonance imaging revealed a giant prostate tumor.
  • The histologic diagnosis was moderately differentiated adenocarcinoma of prostate.
  • The clinical stage according to the TNM classification system was T4N0M0, stage IV.
  • Combined androgen blockade therapy was performed.
  • Four months later, CT showed that the tumor had decreased markedly in size, and the serum prostate specific antigen level was within normal range.
  • Hormone refractory prostate cancer was not found 1 year after the start of treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Chlormadinone Acetate / therapeutic use. Goserelin / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adrenergic alpha-Antagonists / administration & dosage. Aged, 80 and over. Anilides / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Humans. Magnetic Resonance Imaging. Male. Naphthalenes / administration & dosage. Nitriles. Piperazines / administration & dosage. Prostate-Specific Antigen / blood. Tosyl Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352166.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Naphthalenes; 0 / Nitriles; 0 / Piperazines; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; 0SY050L61N / Chlormadinone Acetate; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen; R9PHW59SFN / naftopidil
  •  go-up   go-down


28. Redondo M, Rivas-Ruiz F, Guzman-Soler MC, Labajos C: Monitoring indicators of health care quality by means of a hospital register of tumours. J Eval Clin Pract; 2008 Dec;14(6):1026-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RATIONALE: Hospital registers of tumours provide, on a continuous basis, information on differences in patterns of neoplasias and the results of the treatment strategies employed.
  • Particularly striking was the corresponding delay for breast cancer patients, in most cases superior to 3 months.
  • Thus, non anatomic-pathological diagnoses represented around 7% (range 3-13%), while 43% of patients (range 28-57%) were given adjuvant treatment in the form of radiation therapy or chemotherapy.
  • In 40% of cases (range 20-50%), the tumour stage was included in the clinical record by the doctor who was treating the patient (in the remaining cases, these data were recorded by the Tumour Registry); the date of appearance of the first symptoms was included in the medical record in 65% of cases (range 54-80%).
  • According to the stage classification, the following 5-year survival rates were recorded: (I) 98%, (II) 94%, (III) 69% and (IV) 39% for breast cancer;.
  • (I) 93%, (II) 83%, (III) 68% and (IV) 12% for cancer of the colon; and (I) 100%, (II) 94%, (III) 79% and (IV) 53% for prostate cancer.
  • [MeSH-minor] Humans. Neoplasm Staging. Quality Indicators, Health Care / organization & administration. Quality Indicators, Health Care / statistics & numerical data. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019095.001).
  • [ISSN] 1365-2753
  • [Journal-full-title] Journal of evaluation in clinical practice
  • [ISO-abbreviation] J Eval Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


29. Elliott SP, Jarosek SL, Wilt TJ, Virnig BA: Reduction in physician reimbursement and use of hormone therapy in prostate cancer. J Natl Cancer Inst; 2010 Dec 15;102(24):1826-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction in physician reimbursement and use of hormone therapy in prostate cancer.
  • BACKGROUND: Use of androgen suppression therapy (AST) in prostate cancer increased more than threefold from 1991 to 1999.
  • METHODS: A cohort of 72,818 men diagnosed with prostate cancer in 1992-2005 was identified from the Surveillance, Epidemiology, and End Results database.
  • Non-indicated AST was defined as AST given without other therapies such as radical prostatectomy or radiation in men with low-risk disease (n = 64,788).
  • Covariates in the model included age in 5-year categories, clinical tumor stage (T1-T4), World Health Organization grade (1-3, unknown), Charlson comorbidity (0, 1, 2, ≥ 3), race, education, income, and tumor registry site, all as categorical variables.
  • CONCLUSIONS: In this example of hormone therapy for prostate cancer, decreased physician reimbursement was associated with a reduction in overtreatment without a reduction in needed services.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Medicare.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Jan;167(1):112-6 [11743286.001]
  • [Cites] J Urol. 2008 Nov;180(5):1969-74 [18801512.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-43-8 [12187167.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):599-603 [11836291.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] J Urol. 2001 Aug;166(2):508-15; discussion 515-6 [11458056.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-49-54 [12187168.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] J Urol. 2003 Jan;169(1):251-5 [12478147.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1189-93 [14501722.001]
  • [Cites] Arch Intern Med. 2004 Mar 22;164(6):664-7 [15037496.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Urol. 1995 Aug;154(2 Pt 1):424-8 [7541859.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1013-21 [9060541.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):295-300 [9233866.001]
  • [Cites] N Engl J Med. 2005 Jan 13;352(2):154-64 [15647578.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1615-24 [15742331.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8894-905 [16314650.001]
  • [Cites] Health Aff (Millwood). 2006 Mar-Apr;25(2):437-43 [16522584.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3979-83 [16921050.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4448-56 [16983113.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(4):CD005009 [17943832.001]
  • [Cites] BJU Int. 2008 May;101(9):1077-83 [18190632.001]
  • [Cites] Cancer. 2008 May 15;112(10):2195-201 [18393326.001]
  • [CommentIn] J Natl Cancer Inst. 2010 Dec 15;102(24):1814-5 [21131579.001]
  • (PMID = 21131577.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / 5K12-RR023247-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  • [Other-IDs] NLM/ PMC3001964
  •  go-up   go-down


30. Kiagia M, Karapanagiotou E, Charpidou A, Dilana K, Dionellis G, Dannos I, Georgiou E, Syrigos KN: Rapid infusion of ibandronate in lung cancer patients with bone metastases. Anticancer Res; 2006 Jul-Aug;26(4B):3133-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid infusion of ibandronate in lung cancer patients with bone metastases.
  • BACKGROUND: The high prevalence of bone metastases in stage IV non-small cell lung cancer (NSCLC) patients contributes substantially to the burden of the disease by resulting in significant skeletal morbidity.
  • Ibandronate is a new generation of bisphosphonates (BPs) with demonstrated clinical benefit in breast and prostate cancer patients with bone metastases.
  • With regard to clinical efficacy, 24 of our patients stabilized or reduced their need for analgesic treatment.
  • The reduced time of infusion (20 min vs. 2 h) did not correlate with any side-effects, including vital sign deterioration and renal dysfunction.
  • CONCLUSION: The rapid infusion of ibandronate in lung cancer patients with bone metastases is a safe and convenient procedure that may be administered in a day-clinic setting.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Diphosphonates / administration & dosage. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886646.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down


31. Tomobe M, Miyanaga N, Kawai K, Kikuchi K, Uchida K, Takeshima H, Hasegawa Y, Nagasawa T, Akaza H: [Intrascrotal tumors: a clinicopathologic study of 15 cases]. Nihon Hinyokika Gakkai Zasshi; 2000 Sep;91(9):618-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological diagnoses of 15 patients were 8 malignant lymphomas, 2 paratesticular rhabdomyosarcomas, 2 metastatic tumors (origin; stomach and prostate), 1 epidermoid cyst, 1 cyst of tunica testis, and 1 adenomatoid tumor.
  • As for the cases with malignant lymphoma, all of them were non-Hodgkin's lymphoma whose clinical stages were stage I in 2 cases and stage IV in 6 cases.
  • Five 8 patients died in spite of systemic chemotherapy after an orchiectomy, whereas 2 cases with metastatic tumors died of primary cancer, and two cases with paratesticular rhabdomyosarcoma are still alive and have had no evidence of disease.
  • Therefore, accurate diagnosis and precise treatment is important in the patient with intrascrotal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11068425.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


32. Yao L, Zhou LQ, He ZS, Li XS, Song G, Zhang Z: [Clinical study on intermittent hormonal therapy for patients with prostate cancer]. Beijing Da Xue Xue Bao; 2010 Aug 18;42(4):396-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on intermittent hormonal therapy for patients with prostate cancer].
  • OBJECTIVE: To investigate the effect of intermittent hormonal therapy (IHT) for patients with different stage/grade prostate cancer (PCa).
  • METHODS: The number of cycles and the duration of ON/OFF therapy for 45 PCa patients receiving IHT were observed.
  • Maximal androgen blockade (MAB) therapies were used for six to nine months, and then stopped until the serum prostate specific antigen (PSA) was decreased below 0.2 microg/L, which lasted for three months.
  • RESULTS: The average follow-up time was 40.7+/-13.4 months.
  • Forty-one patients started the second cycle of treatment, of whom, 8 became androgen-independent and 7 were at T3-4M0 or M1 stages and the Gleason scores were above 8.
  • Sixteen patients entered the third cycle, of whom, 14 were at lower than stage III and 13 had the Gleason scores below 7.
  • From the first to the fourth courses of treatment, the average intervals were 8.7+/-5.4 (47.1%), 8.4+/-4.9 (49.3%), 7.0+/-3.4 (43.7%), and 3.7+/-0.6(42.5%) months respectively.
  • Five patients developed bone metastasis.
  • Compared with the intolerance group, the patients who tolerated the treatment well had lower Gleason scores (P=0.002), lower PSA levels (P=0.053) and lower tumor stages (P=0.001).
  • Non-conditional Logistic regression analysis showed that the proportion of patients at stage IV was the only independent risk factor for the tolerance of the treatment (OR=12.113, 95%CI 1.330-110.312, P=0.027).
  • CONCLUSION: Intermittent hormonal therapy is more effective and proper for the patient with highly differentiated tumor and at lower stages (< or = III).
  • The patients who progressed to hormone-independence are mostly at stage IV with poorly differentiated tumor.
  • Intermittent hormone therapy could be more adaptive for the patients at lower than stage III.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Neoplasms, Hormone-Dependent / drug therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721250.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


33. Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N: Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res; 2009 Nov;467(11):2932-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined expression levels of COX-2 immunohistochemically in 51 patients with extremity osteosarcoma who completed standard therapy and obtained complete initial regression of the tumor.
  • We found no correlation between COX-2 staining intensity and variables such as gender, age, anatomic site, necrosis after chemotherapy, and surgical stage.
  • LEVEL OF EVIDENCE: Level IV, prognostic study.
  • [MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / mortality. Bone Neoplasms / therapy. Cyclooxygenase 2 / blood. Osteosarcoma / mortality. Osteosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Confidence Intervals. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pilot Projects. Predictive Value of Tests. Probability. Prognosis. Proportional Hazards Models. Risk Assessment. Survival Analysis. Treatment Outcome. Upper Extremity. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Orthop Res. 1999 Sep;17(5):629-32 [10569469.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Jul;30(7):507-12 [18797196.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):572-7 [10690541.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4064-8 [11051257.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):861-7 [11309334.001]
  • [Cites] Cancer. 2001 May 15;91(10):1876-81 [11346869.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4375-81 [11389063.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] J Bone Joint Surg Br. 2002 Jul;84(5):706-11 [12188489.001]
  • [Cites] J Clin Invest. 2003 Mar;111(5):727-35 [12618527.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Apr;25(4):282-5 [12679640.001]
  • [Cites] J Clin Immunol. 1983 Oct;3(4):295-315 [6140268.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):455-60 [9521170.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):471-4 [9835898.001]
  • [Cites] Eur Respir J. 1999 Aug;14(2):412-8 [10515422.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):33-42 [16327977.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1154-61 [16421923.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):584-92 [16219634.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):70-6 [17536311.001]
  • [Cites] Exp Mol Med. 2007 Aug 31;39(4):469-76 [17934334.001]
  • [Cites] Prostate. 2000 Jan;42(1):73-8 [10579801.001]
  • (PMID = 19326179.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2758970
  •  go-up   go-down


34. Zou YP, Li WM, Zheng F, Li FC, Huang H, Du JD, Liu HR: Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol; 2010 Oct 28;16(40):5104-10
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer.
  • AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with (125)iodine seed implantation for unresectable pancreatic cancer.
  • METHODS: Thirty-two patients (21 males and 11 females) at the age of 68 years (range 48-90 years) with unresectable locally advanced pancreatic cancer admitted to our hospital from January 2006 to May 2008 were enrolled in this study.
  • Diagnosis of pancreatic cancer was made through intraoperative biopsy.
  • In brief, a RFA needle was placed, which was confirmed by intraoperative ultrasound to decrease the potential injury of surrounding vital structures, a (125)iodine seed was implanted near the blood vessels and around the tumor border followed by bypass palliative procedure (cholangio-jejunostomy and/or gastrojejunostomy) in 29 patients.
  • The pain score on day 7 after operation, 1 and 3 mo after combined therapy was decreased from 5.86 ± 1.92 before operation to 2.65 ± 1.04, 1.65 ± 0.88 and 2.03 ± 1.16, respectively, after operation (P < 0.05).
  • The rate of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) in 32 patients was 21.8% (7/32), 56.3% (18/32), 15.6% (5/32) and 6.3% (2/32), respectively, 6 mo after operation, with a median overall survival time of 17. 5 mo.
  • The median survival time of patients at stage III was longer than that of those at stage IV (19 mo vs 10 mo, P = 0.0026).
  • The median survival time of patients who received and did not receive chemotherapy after operation was 20 mo and 16 mo, respectively (P = 0.0176).
  • All the patients recovered well after conservative support treatment.
  • CONCLUSION: Intraoperative RFA combined with (125)iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage III.
  • [MeSH-major] Adenocarcinoma / therapy. Catheter Ablation / methods. Iodine Radioisotopes / therapeutic use. Pancreatic Neoplasms / therapy. Radiotherapy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Feb 1;97(3):554-60 [12548596.001]
  • [Cites] Breast Cancer. 2003;10(1):4-9 [12525756.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1346-52 [12599244.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):85-7 [14736529.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Lancet. 1974 Nov 9;2(7889):1127-31 [4139420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):305-11 [1587751.001]
  • [Cites] Lifetime Data Anal. 1999;5(1):81-90 [10214004.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):392-401 [10462663.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):325-8 [15674746.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):301-14, viii [15831275.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1281-92 [16001679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50 [16029791.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):657-66 [16111466.001]
  • [Cites] Invest Radiol. 2005 Sep;40(9):583-90 [16118551.001]
  • [Cites] Prostate. 2005 Nov 1;65(3):260-7 [16015591.001]
  • [Cites] Eur J Radiol. 2005 Dec;56(3):403-8 [15964164.001]
  • [Cites] JOP. 2006;7(1):1-4 [16407612.001]
  • [Cites] JOP. 2006;7(1):74-8 [16407624.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jan;392(1):55-60 [17089173.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):327-34 [17674961.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] Pancreas. 2000 Jan;20(1):14-20 [10630378.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):332-5 [10722037.001]
  • [Cites] Acta Chir Iugosl. 2002;49(3):19-24 [12587443.001]
  • (PMID = 20976848.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2965288
  •  go-up   go-down


35. Hall IE, Andersen MS, Krumholz HM, Gross CP: Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol; 2009;2009:182521
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is uncertainty about risk heterogeneity for venous thromboembolism (VTE) in older patients with advanced cancer and whether patients can be stratified according to VTE risk.
  • We performed a retrospective cohort study of the linked Medicare-Surveillance, Epidemiology, and End Results cancer registry in older patients with advanced cancer of lung, breast, colon, prostate, or pancreas diagnosed between 1995-1999.
  • We used survival analysis with demographics, comorbidities, and tumor characteristics/treatment as independent variables.
  • Outcome was VTE diagnosed at least one month after cancer diagnosis.
  • Compared to prostate cancer (1.4 VTEs/100 person-years), there was marked variability in VTE risk (hazard ratio (HR) for male-colon cancer 3.73 (95% CI 2.1-6.62), female-colon cancer HR 6.6 (3.83-11.38), up to female-pancreas cancer HR 21.57 (12.21-38.09).
  • Stage IV cancer and chemotherapy resulted in higher risk (HRs 1.75 (1.44-2.12) and 1.31 (1.0-1.57), resp.).
  • Stratifying the cohort by cancer type and stage using recursive partitioning analysis yielded five groups of VTE rates (nonlocalized prostate cancer 1.4 VTEs/100 person-years, to nonlocalized pancreatic cancer 17.4 VTEs/100 patient-years).
  • In a high-risk population with advanced cancer, substantial variability in VTE risk exists, with notable differences according to cancer type and stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Feb 11;318(6):352-5 [3123929.001]
  • [Cites] Blood. 2008 May 15;111(10):4902-7 [18216292.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):677-81 [8594425.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):682-7 [8594426.001]
  • [Cites] Am J Hematol. 1996 Apr;51(4):319-23 [8602634.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):1-7 [8644983.001]
  • [Cites] N Engl J Med. 1997 Sep 4;337(10):663-9 [9278462.001]
  • [Cites] Health Econ. 1994 Nov-Dec;3(6):385-93 [9435921.001]
  • [Cites] Arch Intern Med. 1998 Sep 14;158(16):1809-12 [9738611.001]
  • [Cites] Circulation. 1999 Mar 16;99(10):1325-30 [10077516.001]
  • [Cites] Chest. 1999 Apr;115(4):972-9 [10208194.001]
  • [Cites] N Engl J Med. 1999 Sep 9;341(11):793-800 [10477777.001]
  • [Cites] Medicine (Baltimore). 1999 Sep;78(5):285-91 [10499070.001]
  • [Cites] Ann Intern Med. 2000 Mar 21;132(6):425-34 [10733441.001]
  • [Cites] N Engl J Med. 2000 Dec 21;343(25):1846-50 [11117976.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3712-8 [11533092.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):360-4 [11584190.001]
  • [Cites] Med Care. 2002 Mar;40(3):201-11 [11880793.001]
  • [Cites] Thromb Haemost. 2002 Apr;87(4):575-9 [12008937.001]
  • [Cites] Arch Intern Med. 2002 Jun 10;162(11):1245-8 [12038942.001]
  • [Cites] Thromb Haemost. 2002 Jun;87(6):1076-7 [12083490.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4015-21 [12351599.001]
  • [Cites] Thromb Haemost. 2002 Nov;88(5):745-9 [12428088.001]
  • [Cites] N Engl J Med. 2003 Apr 10;348(15):1425-34 [12601075.001]
  • [Cites] Thromb Haemost. 2003 Mar;89(3):493-8 [12624633.001]
  • [Cites] Arch Intern Med. 2003 Mar 24;163(6):688-92 [12639201.001]
  • [Cites] Semin Thromb Hemost. 2003 Jun;29(3):247-58 [12888929.001]
  • [Cites] J Thromb Haemost. 2003 Dec;1(12):2463-5 [14675077.001]
  • [Cites] Thromb Res. 2003;112(4):203-7 [14987912.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] Am J Med. 2004 Jul 1;117(1):19-25 [15210384.001]
  • [Cites] Circulation. 2004 Aug 17;110(7):874-9 [15289368.001]
  • [Cites] Chest. 2004 Sep;126(3 Suppl):338S-400S [15383478.001]
  • [Cites] J Clin Pathol. 2004 Dec;57(12):1254-7 [15563663.001]
  • [Cites] Thromb Haemost. 2005 Jan;93(1):76-9 [15630494.001]
  • [Cites] JAMA. 2005 Feb 9;293(6):715-22 [15701913.001]
  • [Cites] Thromb Haemost. 2005 Feb;93(2):284-8 [15711744.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):297-303 [16282243.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):289-96 [16317012.001]
  • [Cites] Arch Intern Med. 2006 Feb 27;166(4):458-64 [16505267.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1112-8 [16505431.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Sep;59(3):211-7 [16806961.001]
  • [Cites] Eur Heart J. 2006 Aug;27(16):1954-64 [16847008.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):70-6 [17194906.001]
  • [Cites] J Gen Intern Med. 2007 Mar;22(3):321-6 [17356962.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2339-46 [17918266.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2119-52 [17939129.001]
  • [Cites] J Thromb Haemost. 2008 Apr;6(4):601-8 [18208538.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • (PMID = 20445797.001).
  • [ISSN] 1687-8566
  • [Journal-full-title] Journal of cancer epidemiology
  • [ISO-abbreviation] J Cancer Epidemiol
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / K08 AG024842
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2859683
  •  go-up   go-down


36. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab; 2006 Jun;91(6):1995-2010
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline.
  • OBJECTIVE: The objective was to provide guidelines for the evaluation and treatment of androgen deficiency syndromes in adult men.
  • At each stage of review, the Task Force received written comments and incorporated needed changes.
  • We recommend testosterone therapy for symptomatic men with androgen deficiency, who have low testosterone levels, to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density.
  • We recommend against starting testosterone therapy in patients with breast or prostate cancer, a palpable prostate nodule or induration or prostate-specific antigen greater than 3 ng/ml without further urological evaluation, erythrocytosis (hematocrit > 50%), hyperviscosity, untreated obstructive sleep apnea, severe lower urinary tract symptoms with International Prostate Symptom Score (IPSS) greater than 19, or class III or IV heart failure.
  • When testosterone therapy is instituted, we suggest aiming at achieving testosterone levels during treatment in the mid-normal range with any of the approved formulations, chosen on the basis of the patient's preference, consideration of pharmacokinetics, treatment burden, and cost.
  • Men receiving testosterone therapy should be monitored using a standardized plan.
  • [MeSH-major] Testosterone / deficiency. Testosterone / therapeutic use
  • [MeSH-minor] Evidence-Based Medicine. Glucocorticoids / adverse effects. HIV Infections / blood. Humans. Male. Sexual Dysfunction, Physiological / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Endocrinol Metab. 2007 Feb;92(2):414-5 [17284641.001]
  • [CommentIn] J Clin Endocrinol Metab. 2007 Feb;92(2):418-9 [17284643.001]
  • [CommentIn] J Clin Endocrinol Metab. 2007 Feb;92(2):416-7 [17284642.001]
  • [ErratumIn] J Clin Endocrinol Metab. 2006 Jul;91(7):2688
  • (PMID = 16720669.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 3XMK78S47O / Testosterone
  •  go-up   go-down


37. Yi SK, Yoder M, Zaner K, Hirsch AE: Palliative radiation therapy of symptomatic recurrent bladder cancer. Pain Physician; 2007 Mar;10(2):285-90
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy of symptomatic recurrent bladder cancer.
  • BACKGROUND: Palliative radiation therapy (RT) is an established tool in the management of symptoms caused by malignancies.
  • RT is effective at palliating both locally advanced and metastatic cancer, including related symptoms of pain, bleeding, or obstruction.
  • Most data on palliative RT is in regard to its use in the treatment of painful bone metastases.
  • There are also data that support RT palliation for locally advanced or recurrent rectal, prostate, and gynecological cancers.
  • With regard to bladder cancer there is some evidence of the benefit of palliative RT for the control of urinary symptoms and hematuria; however, there is little evidence for the use of palliative RT for pain associated with locally recurrent bladder cancer.
  • We report a case of locally advanced recurrent bladder cancer which was refractory to medical pain management, and was found to be highly responsive to palliative RT.
  • CASE REPORT: An 80-year-old woman with recurrent bladder cancer and intractable pelvic pain refractory to oral and transdermal pain medications, received palliative pelvic RT to a dose of 50 Gy (5000 cGy) in 25 fractions with complete resolution of pain.
  • The patient was originally found to have dysuria, frequency, and hematuria, secondary to an invasive high grade transitional cell carcinoma of the bladder with an adenocarcinoma component, AJCC pT2b N1 M0 Stage IV, for which she underwent a radical cystectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial vaginectomy, and ileal conduit reconstruction.
  • After undergoing 4 cycles of adjuvant chemotherapy, the patient did well for 5 months with no evidence of symptomatic, clinical, or radiographic recurrence of disease.
  • The patient was treated with another course of chemotherapy and pain was managed with relatively low doses of opioid medication (25mcg transdermal fentanyl patch, and oxycodone 5mg bid).
  • Ultimately a pain medication regimen of 200mcg transdermal fentanyl patch q2 days, oxycontin 20mg bid, oxycodone 5 - 10mg q 4 hours, ibuprofen 400mg q 8 hours, and gabapentin 600mg TID was not effective in controlling pain.
  • She was able to decrease pain medications, increase overall activity, and gain significant improvement in sleep quality and appetite even early on in the course of her radiation therapy.
  • CONCLUSIONS: Palliative radiation therapy has been well studied in the setting of bone metastases and treatment of hematuria for locally advanced bladder cancer.
  • There is little data that we are aware of on the use of RT for pain control with patients that have recurrent, locally advanced bladder cancer.
  • RT is an excellent option for pain management in recurrent bladder cancer and should be offered to patients whose pain is not otherwise optimally controlled.
  • Palliative RT is an important component in the multimodality approach to cancer pain management and optimization of quality of life.
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Quality of Life. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387350.001).
  • [ISSN] 1533-3159
  • [Journal-full-title] Pain physician
  • [ISO-abbreviation] Pain Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Yee EF, White RE, Murata GH, Handanos C, Hoffman RM: Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med; 2007 Sep;22(9):1305-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy.
  • BACKGROUND: The use of androgen deprivation therapy (ADT) for prostate cancer has increased substantially in recent years, exposing more men to potential treatment complications, including osteoporosis and fractures.
  • OBJECTIVE: To determine whether men treated with ADT for prostate cancer received osteoporosis screening, prevention, or treatment.
  • SUBJECTS: One hundred seventy-four patients with prostate cancer on ADT or status-post orchiectomy enrolled in primary care at the New Mexico Veterans Affairs Health Care System as of July 2005.
  • MEASUREMENTS: Patient demographics, tumor characteristics (Gleason score, stage, last PSA value, documented bone metastases), history of hip or vertebral fracture, osteoporosis risk factors (number of ADT shots, diabetes, smoking, heavy alcohol use or prescriptions for corticosteroids, thyroid hormone or dilantin).
  • RESULTS: Just 60 of 174 (34%) patients received recommended osteoporosis management based on DXA scans (13%) or treatment with oral or IV bisphosphonates (21%), calcitonin (1%), calcium (16%) or vitamin D (10%).
  • CONCLUSIONS: Most men treated with ADT for prostate cancer did not receive osteoporosis screening, prevention or treatment.
  • Evidence for advanced cancer though not risk factors for osteoporosis or fracture-was associated with receiving osteoporosis management.
  • Further research is needed to identify optimal strategies for screening, prevention, and treatment in this population.
  • [MeSH-major] Androgens / deficiency. Hormone Antagonists / therapeutic use. Osteoporosis / drug therapy. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Osteoporosis.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Osteoporos Int. 2003 Apr;14(2):123-9 [12730780.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):238-44 [16014598.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1444-50 [11745221.001]
  • [Cites] Mayo Clin Proc. 2002 Apr;77(4):334-8 [11936928.001]
  • [Cites] J Urol. 2002 Jun;167(6):2361-7; discussion 2367 [11992038.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3656-61 [12161491.001]
  • [Cites] Mayo Clin Proc. 2002 Aug;77(8):875; author reply 875-6 [12173724.001]
  • [Cites] J Urol. 2002 Sep;168(3):1005-7 [12187209.001]
  • [Cites] Urology. 2002 Sep;60(3 Suppl 1):7-11; discussion 11-2 [12231037.001]
  • [Cites] J Urol. 2000 Jan;163(1):181-6 [10604342.001]
  • [Cites] Health Educ Res. 2000 Apr;15(2):153-62 [10751374.001]
  • [Cites] N Engl J Med. 2000 Aug 31;343(9):604-10 [10979796.001]
  • [Cites] N Engl J Med. 2001 Sep 27;345(13):948-55 [11575286.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68 [12359855.001]
  • [Cites] Arch Intern Med. 2002 Oct 28;162(19):2217-22 [12390065.001]
  • [Cites] CMAJ. 2002 Nov 12;167(10 Suppl):S1-34 [12427685.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3136-42 [12483716.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):789-95 [12548577.001]
  • [Cites] J Urol. 2003 May;169(5):1747-50 [12686824.001]
  • [Cites] J Urol. 2003 Jun;169(6):2008-12 [12771706.001]
  • [Cites] Am J Med. 2003 Sep;115(4):309-17 [12967696.001]
  • [Cites] Am J Med. 2003 Oct 1;115(5):398-400 [14553876.001]
  • [Cites] Arch Intern Med. 2003 Oct 13;163(18):2165-72 [14557214.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2796; author reply 2796-7 [14662645.001]
  • [Cites] J Clin Densitom. 2004 Spring;7(1):37-44 [14742886.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):892-9 [14983482.001]
  • [Cites] Rheumatol Int. 2004 Mar;24(2):110-3 [13680141.001]
  • [Cites] Urol Clin North Am. 2004 May;31(2):331-52 [15123412.001]
  • [Cites] Arch Intern Med. 2004 May 24;164(10):1047-8 [15159261.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2141-9 [15169800.001]
  • [Cites] J Gen Intern Med. 2004 Jul;19(7):783-90 [15209594.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):541-9 [15274067.001]
  • [Cites] Am Fam Physician. 2004 Oct 1;70(7):1219-20 [15508531.001]
  • [Cites] Calcif Tissue Int. 1995 Aug;57(2):97-9 [7584882.001]
  • [Cites] Arch Intern Med. 1998 Sep 14;158(16):1789-95 [9738608.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1561-6 [9781950.001]
  • [Cites] Lancet. 1999 Mar 13;353(9156):878-82 [10093980.001]
  • [Cites] J Urol. 2004 Dec;172(6 Pt 1):2137-44 [15538219.001]
  • [Cites] N Engl J Med. 2005 Jan 13;352(2):154-64 [15647578.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):237-41 [15597384.001]
  • [Cites] Osteoporos Int. 2005 Jun;16(6):707-11 [15714259.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7897-903 [16258089.001]
  • [Cites] J Urol. 2006 Jan;175(1):136-9; discussion 139 [16406890.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Mayo Clin Proc. 2006 May;81(5):662-72 [16706264.001]
  • [Cites] J Endocrinol Invest. 2006 May;29(5):467-70 [16794372.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4448-56 [16983113.001]
  • [Cites] Ann Intern Med. 2007 Mar 20;146(6):416-24 [17371886.001]
  • [Cites] J Urol. 2001 Nov;166(5):1724-8 [11586210.001]
  • (PMID = 17634780.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Hormone Antagonists
  • [Other-IDs] NLM/ PMC2219777
  •  go-up   go-down


39. Merseburger AS, Müller CC, Merseburger Schönborn CT, Ostertag H, Kuczyk MA: [A rare case of isolated prostate metastasis from primary pancreatic cancer]. Urologe A; 2005 May;44(5):527-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare case of isolated prostate metastasis from primary pancreatic cancer].
  • [Transliterated title] Seltener Fall der Metastase eines Pankreaskarzinoms in die Prostata.
  • A transrectal biopsy confirmed the intraprostatic lesion as a metastatic lesion from pancreatic cancer.
  • Therefore, we report this unusual case of a primary pancreatic carcinoma, clinical stage IV, which led to metastases in the liver and prostate.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / secondary. Pancreatic Neoplasms / diagnosis. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / secondary. Rare Diseases / diagnosis. Rare Diseases / drug therapy


40. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst; 2006 Jun 21;98(12):839-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
  • BACKGROUND: The use of androgen deprivation therapy for prostate cancer has been increasing, even in settings for which there is weak or no evidence of efficacy.
  • We assessed the importance of the physician as a determinant of the use of androgen deprivation therapy in prostate cancer in a population-based, retrospective cohort study using the Surveillance, Epidemiology and End-Results-Medicare linked database.
  • METHODS: Participants included 61 717 men with incident prostate cancer diagnosed from January 1, 1992, through December 31, 1999, and 1802 urologists providing care to them within 1 year of cancer diagnosis.
  • Multilevel analyses were used to estimate and partition the variance in use of androgen deprivation therapy within 6 months of diagnosis between patient or tumor characteristics and urologist to examine the relative contribution of each component to androgen deprivation therapy.
  • RESULTS: The percentage of the total variance in the use of androgen deprivation therapy attributable to the urologist was consistently higher than that attributable to tumor or patient characteristics.
  • This pattern was most pronounced for patients diagnosed from January 1, 1997, through December 31, 1999, in which 22.56% of the total variance in use of androgen deprivation therapy was attributable to the urologist, 9.71% to tumor characteristics (stage or grade), and 4.29% to patient characteristics (age, ethnicity, socio-economic status, comorbidity, geographic region, or year of diagnosis).
  • CONCLUSIONS: Which urologist a patient sees may be more important in determining whether they will receive androgen deprivation therapy than tumor or patient characteristics.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2000 Apr 4;132(7):566-77 [10744594.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] QJM. 2001 Jun;94(6):301-8 [11391028.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):407-9 [11904307.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [Cites] Urology. 2002 Aug;60(2):201-8 [12137810.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-82-95 [12187173.001]
  • [Cites] Med Care. 2002 Aug;40(8):650-61 [12187179.001]
  • [Cites] Urology. 2002 Sep;60(3 Suppl 1):7-11; discussion 11-2 [12231037.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):981-9 [12837834.001]
  • [Cites] Curr Opin Urol. 2004 May;14(3):177-83 [15069309.001]
  • [Cites] Sci Am. 1982 Apr;246(4):120-34 [7079718.001]
  • [Cites] Soc Sci Med. 1982;16(7):811-24 [7100999.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] N Engl J Med. 1989 Aug 17;321(7):419-24 [2503724.001]
  • [Cites] J Clin Epidemiol. 1991;44(4-5):381-90 [2010781.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] J Urol. 1995 Jul;154(1):207-8 [7539862.001]
  • [Cites] Med Care. 1996 Jun;34(6):594-609 [8656725.001]
  • [Cites] Med Care. 1996 Sep;34(9 Suppl):SS87-101 [8792792.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1013-21 [9060541.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):295-300 [9233866.001]
  • [Cites] Med Care. 1998 Feb;36(2):212-29 [9475475.001]
  • [Cites] J Urol. 1998 Jun;159(6):1993-6; discussion 1996-7 [9598505.001]
  • [Cites] JAMA. 1999 Feb 24;281(8):720-6 [10052442.001]
  • [Cites] JAMA. 1999 Jun 9;281(22):2098-105 [10367820.001]
  • [Cites] Scand J Public Health. 1999 Sep;27(3):173-80 [10482075.001]
  • [Cites] N Engl J Med. 2005 Jan 13;352(2):154-64 [15647578.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1615-24 [15742331.001]
  • [Cites] Arch Intern Med. 2006 Feb 27;166(4):465-71 [16505268.001]
  • [CommentIn] J Natl Cancer Inst. 2006 Jun 21;98(12):802-3 [16788149.001]
  • (PMID = 16788157.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / AHRQ HHS / HS / R24 HS011618; United States / NCI NIH HHS / CA / R01CA116758; United States / NCI NIH HHS / CA / R01 CA116758; United States / AHRQ HHS / HS / R24HS011618; United States / NCI NIH HHS / CA / P50CA105631; United States / NCI NIH HHS / CA / P50 CA105631
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  • [Other-IDs] NLM/ NIHMS19896; NLM/ PMC1853355
  •  go-up   go-down


41. Hori J, Kato Y, Iwata T, Taniguchi N, Hashimoto H, Yachiku S: [A case of penile malignant melanoma]. Hinyokika Kiyo; 2003 Aug;49(8):493-6
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystoscopy and urethrography revealed urethral invasion of malignant melanoma, and magnetic resonance imaging (MRI) of the penis revealed invasion to prostate, and pelvic lymph node metastases in abdominal compuled tomography (CT) but no organ metastases.
  • After these therapies, chemotherapy was performed.
  • Five months later, CT revealed multiple lung and brain metastases, and radiation therapy and chemotherapy were performed.
  • Twelve months after the operation, he died of cancer.
  • In 30 cases, stage III, IV were 20 cases and 16 cases performed operation.
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518390.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down






Advertisement